GLP-1 Analogues in Weight Loss Supplements: The Undeclared Drug Problem FDA Is Targeting in 2026

Walk into any supplement retail aisle — or scroll through Amazon’s health section — and you’ll find dozens of products promising to “support GLP-1 levels” or “activate your body’s natural weight-loss pathways.” Most are selling berberine, glucomannan, or bitter melon extract. Some, based on FDA enforcement data from the past 18 months, are selling something considerably more dangerous: actual GLP-1 receptor agonists.

That distinction matters enormously. Semaglutide and tirzepatide are FDA-approved prescription drugs. They carry real clinical risk profiles — pancreatitis concerns, thyroid C-cell tumor signals in animal studies, severe GI effects — and they’re dosed with precision under medical supervision. Finding them undeclared in a supplement capsule is a serious public health problem, and it’s exactly the kind of adulteration that’s been generating FDA warning letters and import alerts with increasing frequency.

If you’re manufacturing or selling weight-loss supplements right now, this trend deserves your full attention.

What GLP-1 Analogues Are — and Why They’re Appearing in Supplements

GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone that stimulates insulin secretion and suppresses appetite. The pharmaceutical industry has built an extraordinary drug class around synthetic analogs of this peptide — semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound) among them. Novo Nordisk and Eli Lilly combined generated over $40 billion in GLP-1 drug revenue in 2024 alone. Consumer demand is unlike anything the weight-loss category has seen in decades.

That demand has created an obvious opportunity for fraud. Consumers who can’t access prescription GLP-1 drugs — because of cost, insurance barriers, or access — are turning to the supplement market in large numbers. The US weight-loss supplement market sits at roughly $10 billion annually, and a significant slice of that growth is being driven by products that position themselves adjacent to the GLP-1 story.

Most of these products are perfectly legal. They contain ingredients like berberine (which has shown some GLP-1 pathway activity in early mechanistic research), inositol, or botanical adaptogens. The legal problem starts when a manufacturer, looking to make its formula actually deliver results, adds a pharmaceutical-grade GLP-1 agonist to the product without listing it on the label.

Under 21 CFR Section 321(g)(1), any article intended to affect the structure or function of the body in a drug-like way — and certainly any product containing a known drug ingredient — is legally a drug, regardless of whether it’s packaged in a supplement bottle. Add semaglutide to a capsule and sell it as a “metabolic support formula,” and you’ve manufactured an adulterated drug product without a New Drug Application. That’s not a labeling technicality. It’s a federal violation that can result in product seizure, injunctions, and criminal referrals.

What FDA’s Enforcement Actions Are Revealing

FDA’s Office of Regulatory Affairs has intensified its posture on this category considerably. Weight management and sexual enhancement supplements have historically topped the agency’s adulterant surveillance priorities — and GLP-1-class compounds are now explicitly part of what CFSAN’s Dietary Supplement Program is screening for.

The adulterant picture here is more complex than the older generation of stimulant-based weight-loss fraud (sibutramine, fenfluramine, phenolphthalein) that dominated enforcement actions a decade ago. Some of the products appearing in recent import alerts and warning letters don’t contain fully characterized semaglutide itself, but peptide analogs and fragments with partial GLP-1 receptor agonist activity — compounds that are structurally similar enough to produce physiological effects while potentially evading standard drug screening databases.

From a consumer harm standpoint, the risk profile is not theoretical. A consumer ingesting an unlabeled GLP-1 agonist doesn’t know their effective dose, has no medical supervision, and may be combining the compound with insulin or other diabetes medications — a combination that can cause dangerous hypoglycemia. Reports of adverse events associated with adulterated weight-loss supplements have been logged in FDA’s CFSAN Adverse Event Reporting System (CAERS), and the lag between initial sale and adverse event detection is a persistent challenge for the agency.

How LC-MS/MS Testing Catches What Label Reviews Can’t

Standard label compliance testing — confirming that a supplement’s declared ingredients are present at stated potencies — will never catch an undeclared drug. You can only find what you’re looking for. Detecting GLP-1 agonists and their analogs requires a fundamentally different analytical approach.

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the workhorse method for pharmaceutical adulterant screening in dietary supplements. The technique separates compounds chromatographically and identifies them by their characteristic mass-to-charge ratios and fragmentation patterns — a molecular fingerprint that’s essentially impossible to mimic or disguise. Modern LC-MS/MS systems can detect drug analytes at sub-nanogram-per-gram concentrations, which means even trace-level contamination won’t slip through a well-developed method.

For GLP-1 agonist screening specifically, two technical challenges complicate the analysis. First, semaglutide and similar compounds are large peptide molecules — semaglutide has a molecular weight of approximately 4,114 Da — which behave very differently under reversed-phase chromatographic conditions compared to small-molecule drugs. Method development requires careful optimization of mobile phase gradients and electrospray ionization parameters. Second, the novel analogs and truncated peptide fragments that some manufacturers are using as workarounds don’t always appear in published drug compound databases, which means a defensible screening program needs to combine targeted methods (known compound libraries) with suspect-screening or untargeted approaches that can flag structurally similar unknowns.

At our lab, we’ve expanded our pharmaceutical adulterant screening panel specifically to include GLP-1-class compounds in response to the uptick in enforcement activity and brand inquiries. It’s not a test that every supplement category warrants — a botanical fiber product doesn’t need GLP-1 screening. But for any weight-management formula making appetite suppression or metabolic claims, it’s now a baseline that responsible brands should be meeting.

The Compliance Gap Most Brands Haven’t Closed

Here’s the uncomfortable part of the liability picture for brands sourcing from contract manufacturers: if your CMO is adding undeclared drug ingredients to hit a weight-loss performance expectation, you — as the brand — carry legal exposure.

Under 21 CFR Part 111 (GMP regulations for dietary supplements), finished product testing and supplier qualification are ultimately the brand owner’s responsibility. FDA’s enforcement posture makes clear that “we didn’t know our CMO was adulterating” is not a compliant answer. It’s evidence of an inadequate quality system. A warning letter issued against your label is your problem, regardless of where the adulteration originated in the supply chain.

Amazon has independently been tightening requirements in this direction. Weight-management supplements in high-risk sub-categories are subject to expanded third-party testing documentation requirements on the marketplace, and submissions lacking pharmaceutical adulterant screening data are drawing additional review from Amazon’s health and safety compliance team. A retailer delisting is faster and less formal than an FDA enforcement action — and it can happen before you’ve had any regulatory contact at all.

What a Defensible Testing Program Looks Like Right Now

For a weight-management supplement brand in 2026, a defensible testing program should include, at minimum:

Finished product third-party testing from an ISO 17025-accredited laboratory covering label claim verification, pharmaceutical adulterant screening via LC-MS/MS (including GLP-1-class peptides, stimulants, and drug categories relevant to your formula’s claims), heavy metals, and microbial limits per USP <61>/<62>.

Supplier qualification documentation that goes beyond a COA for declared ingredients. For contract-manufactured products, require your CMO to certify — in writing, with supporting test data — that finished product has been screened for relevant adulterant categories before shipment.

Ongoing monitoring of FDA’s Tainted Products Marketed as Dietary Supplements database. The database is publicly searchable at accessdata.fda.gov. Reviewing it at product launch and quarterly thereafter should be routine. If a compound has already been found in products making similar claims to yours, it belongs on your screening list.

A documented change control process so that formula or supplier changes trigger a new round of adulterant screening — not just label claim verification. Adulteration risk can shift when raw material sources change.

None of this is novel regulatory territory. It’s what 21 CFR Part 111 has required all along. What’s changed is the specific adulterant landscape — and the speed at which FDA, Amazon, and major retailers are acting on it. The brands that are going to have a problem this year aren’t necessarily the ones knowingly selling adulterated supplements. They’re the ones whose testing programs haven’t kept pace with the adulterant landscape, and who won’t find out until FDA does.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Building an FDA-Audit-Ready Compliance Program for Supplement Brands — Aurora TIC helps dietary supplement companies develop quality systems and documentation frameworks that hold up under regulatory scrutiny.
• Raw Material Supplier Qualification and COA Verification — Ayah Labs specializes in verifying supplier documentation and testing incoming raw materials before they reach your production line.
• Weight-Loss Supplement Compliance Under Health Canada’s NHP Regulations — Androxa covers the Canadian side of the compliance picture for brands selling weight-management products in Canada.